Overview

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Status:
Completed
Trial end date:
2017-07-06
Target enrollment:
Participant gender:
Summary
To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single administration of TS-143.
Phase:
Phase 1
Details
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.